SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the iStent inject® Trabecular Micro-Bypass System indicated for the reduction of intraocular
Neopenda, a medical device startup based in Chicago, is developing medical solutions for low-resource settings, and has recently unveiled its first product, a wearable vital signs monitor for newborns. The company has reported that almost 3 million babies die within the first month of life. Up to 98% of these deaths occur in developing countries, [ (Read more...)
Our eye hosts a powerful biological computer, the retina. Understanding how the retina transforms images from the outside world into signals that the brain can interpret would not only result in insights into brain computations, but could also be usefu…
KIAWAH ISLAND, S.C. – At the Kiawah Eye meeting, OSN Glaucoma Board Member Savak “Sev” Teymoorian, MD, MBA, talks about tailoring glaucoma care by targeting different anatomical sites and combining minimally invasive glaucoma surgery procedures.
KIAWAH ISLAND, S.C. – At the Kiawah Eye meeting, OSN Glaucoma Section Editor Thomas W. Samuelson, MD, discusses canal -based glaucoma procedures, highlighting two new minimally invasive glaucoma surgery devices pending FDA approval, the Glaukos second generation iStent inject and the Ivantis Hydrus.
KIAWAH ISLAND, S.C. – At the Kiawah Eye meeting, Reay H. Brown, MD, discusses the role of the Alcon CyPass micro-stent in the context of the current minimally invasive glaucoma surgery landscape.